HC Wainwright & Co. Maintains Buy on Oncternal Therapeutics, Lowers Price Target to $18
HC Wainwright & Co. Maintains Buy on Oncternal Therapeutics, Lowers Price Target to $18
HC Wainwright & Co.維持對oncternal therapeutics的買入評級,將目標價格下調至18美元。
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Oncternal Therapeutics (NASDAQ:ONCT) with a Buy and lowers the price target from $19 to $18.
HC Wainwright & Co. 分析師Raghuram Selvaraju維持Oncternal Therapeutics (納斯達克: ONCT)爲買入並將價格目標從19美元降至18美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。